Notice of AGM

Summary by AI ^BETAClose X

Cizzle Biotechnology Holdings PLC has announced that its notice of Annual General Meeting has been posted to shareholders and will be available on the company's website, with the meeting scheduled for 11:00 a.m. on Tuesday, 16 June 2026. The company, a UK-based diagnostics developer focused on early cancer tests, is known for its CIZ1B biomarker technology for non-invasive lung cancer detection.

Disclaimer*

Cizzle Biotechnology Holdings PLC

21 May 2026

Cizzle Biotechnology Holdings plc

("Cizzle", "Cizzle Biotechnology", or the "Company")

Notice of Annual General Meeting

Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, announces that the Company's notice of Annual General Meeting has been posted to shareholders and will shortly be available for viewing on the Company's website at https://cizzlebiotechnology.com.

The Annual General Meeting will be held at 11:00 a.m. on Tuesday 16 June 2026 at the offices of Shakespeare Martineau LLP, C/O Ampa Holdings LLP, Level 19, The Shard, 32 London Bridge Street, London, United Kingdom, SE1 9SG.

Enquiries:

Cizzle Biotechnology Holdings plc	Via IFC Advisory
Allan Syms (Executive Chairman)

Allenby Capital Limited	+44(0) 20 3328 5656
John Depasquale (Corporate Finance)
Amrit Nahal (Sales and Corporate Broking)

IFC Advisory Limited	+44(0) 20 3934 6632
Tim Metcalfe
Florence Staton

About Cizzle Biotechnology

The CIZ1B biomarker is a naturally occurring variant of the cell nuclear protein CIZ1, which is linked with the preservation of epigenetic integrity. CIZ1B is highly associated with the presence of early-stage lung cancer and can be measured in small quantities of blood. The Company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021.

For more information, please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END